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Abstract
Studies on the role of B lymphocytes in atherosclerosis development, have yielded contra-
dictory results. Whereas B lymphocyte-deficiency aggravates atherosclerosis in mice;
depletion of mature B lymphocytes reduces atherosclerosis. These observations led to the
notion that distinct B lymphocyte subsets have different roles. B1a lymphocytes exert an
atheroprotective effect, which has been attributed to secretion of IgM, which can be depos-
ited in atherosclerotic lesions thereby reducing necrotic core formation. Tumor necrosis
factor (TNF)-family member ‘A Proliferation-Inducing Ligand’ (APRIL, also known as
TNFSF13) was previously shown to increase serum IgM levels in a murine model. In this
study, we investigated the effect of APRIL overexpression on advanced lesion formation
and composition, IgM production and B cell phenotype. We crossed APRIL transgenic
(APRIL-Tg) mice with ApoE knockout (ApoE-/-) mice. After a 12-week Western Type Diet,
ApoE-/-APRIL-Tg mice and ApoE-/- littermates showed similar increases in body weight and
lipid levels. Histologic evaluation showed no differences in lesion size, stage or necrotic
area. However, smooth muscle cell (α-actin stain) content was increased in ApoE-/-APRIL-
Tg mice, implying more stable lesions. In addition, increases in both plaque IgM deposition
and plasma IgM levels were found in ApoE-/-APRIL-Tg mice compared with ApoE-/- mice.
Flow cytometry revealed a concomitant increase in peritoneal B1a lymphocytes in
ApoE-/-APRIL-Tg mice. This study shows that ApoE-/-APRIL-Tg mice have increased
oxLDL-specific serum IgM levels, potentially mediated via an increase in B1a lymphocytes.
Although no differences in lesion size were found, transgenic ApoE-/-APRIL-Tg mice do
show potential plaque stabilizing features in advanced atherosclerotic lesions.
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Introduction
With the increasing recognition of atherosclerosis as an inflammatory disease [1], understand-
ing the role of different immune cells is pivotal for therapeutic targeting of the inflammatory
process during atherogenesis. Amongst the immune cells involved in atherosclerosis, studies
on the role of B lymphocytes have yielded contradictory results. In humans, early data suggest-
ing a role for B lymphocytes in atherosclerosis was derived from a study in war veterans, show-
ing that trauma-induced splenectomy is associated with a high rate of acute myocardial
infarction [2]. This was corroborated by genome wide association data, supporting a protective
role of B lymphocytes in atherosclerosis [3].
In murine models, however, conflicting results have been found. B lymphocyte-deficient
mice had accelerated atherosclerosis [4]. Conversely, mature B lymphocyte depletion by anti-
CD20 antibodies reduced atherosclerosis [5,6]. These observations led to the notion of distinct
B lymphocyte subsets with different roles. Whereas B2 lymphocytes seem to aggravate athero-
sclerosis [5], B1a lymphocytes have atheroprotective properties [7], potentially through secre-
tion of natural IgM [8], which can be deposited in atherosclerotic lesions. IgM is thought to
play a role in the clearance of oxidized LDL (OxLDL) and apoptotic cells [9], thereby reducing
the necrotic core [8]. Low IgM levels in general (independent of their specific epitope) are asso-
ciated with increased lesion formation [10], and infusion of polyclonal IgM reduced accelera-
tion of lesion progression in mice [11], supporting that overall increases in IgM levels have
atheroprotective properties. Also in humans, IgM antibodies have been shown to have an
inverse correlation to carotid atherosclerosis [12] and CVD risk [13].
The tumor necrosis factor (TNF)-family members B-cell activating factor (BAFF) and ‘A
Proliferation-Inducing Ligand’ (APRIL, also known as TNFSF13) [14] are critical regulators of
B cell homeostasis [15]. In murine models of collagen induced arthritis BAFF and APRIL are
suggested to have opposite effects: BAFF promotes inflammatory processes, whereas overex-
pression of APRIL suppressed experimental arthritis, potentially mediated via selective
increases in plasma IgM levels [16]. In atherogenesis, BAFF receptor-deficiencywas shown to
decrease atherosclerosis, by depleting B2 but not B1a lymphocytes [7,17]. Both RNA and pro-
tein expression of BAFF and APRIL have been shown in human atherosclerotic tissue and
plasma [18,19]. The role of APRIL in atherosclerosis has not yet been investigated. In the pres-
ent study, we hypothesized that ectopic APRIL expression on an atherosclerotic background
(ApoE knockout mice), would reduce atherosclerotic lesion formation through increased IgM
production.
Methods
Animals and Experimental Design
Heterozygous APRIL-Tg C57BL/6.J mice, which express human APRIL under control of the
LCK distal promoter (as described in detail previously), [16] (kindly provided by Dr. M.
Hahne) were crossed with ApoE knockout (ApoE-/-) C57BL/6.J mice (purchased from Charles
River, Jackson Laboratories, Bar Harbor, Maine). Genotype was established by polymerase
chain reaction on DNA isolated from the toe. The ApoE-specific primer set was: forward
5’GCCTAGCCGAGGGAGAGCCG-3’;Wild type reverse 5’-TGTGACTTGGGAGCTCTG
CAGC-3’; Mutant reverse 5’-GCCGCCCCGACTGCATCT-3’. The APRIL-specific primer set
was: forward 5’-ATGGATTACAAAGACGATGACG-3’ and reverse 5’-TCACAGTTTCACA
AACCCCAGG-3’. 12–14Weeks old female ApoE-/-APRIL-Tg mice and ApoE-/- littermates
were fed a Western Type Diet (WTD, Abdiets, Woerden, the Netherlands) containing 0.25%
(w/w) cholesterol and 16% (w/w) fat for 12 weeks. Body weight was determined every week.
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Blood samples (tail snip) were taken at t = 0 and t = 6 weeks after a 4 hour fasting period. At
t = 12 weeks mice were first fasted for 4 hours and sacrificedby an intra-peritoneal ketamine
(238 mg/kg) / xylazine (24 mg/kg) injection. Blood was collected through orbital bleeding and
plasma was stored at -20°C until use. Peritoneal lavage was performedwith 5ml of ice-cold
phosphate-buffered saline (PBS; Fresenius Kabi, Zeist, The Netherlands). Hearts were cut per-
pendicular to the heart axis just below the atrial tips, embedded in paraffin and 7μM sections
were made. Aorta’s and Lymph nodes were snap frozen. Animal experiments were performed
in compliance with Dutch national and institutional guidelines and approved by the Commit-
tee for AnimalWelfare of AmsterdamMedical Centre (Permit Number DRI102945). All
efforts were made to minimize animal suffering.More detailed information on experimental
procedures, animals and housing is available in S1 Text.
Mouse blood parameters
White blood cells (WBC), Red blood cells (RBC), platelets and hematocrit (Hct) were mea-
sured using a ScilVet abc plus+ (ScilVet, Oostelbeers, The Netherlands). Plasma triglyceride
levels were measured colorimetrically (GPO-PAP, Roche,Woerden, The Netherlands) and
plasma total cholesterol was determined enzymatically (CHOD-PAP, Roche,Woerden, The
Netherlands) according to the manufacturer's instructions. Total plasma IgM and IgG levels
were determined by using a standard ELISA technique. Briefly, plates were coated overnight at
4°C with goat anti-mouse Ig(H+L) (Southern Biotech, Birmingham, LA, USA). Plasma samples
were incubated for 2 hours at room temperature followed by a goat-anti-mouse IgM-HRP or
goat anti-mouse IgG(H+L) human ads-HRP (Southern Biotech, Birmingham, LA, USA). IgM
and IgG levels were visualized by using ABTS Elisa peroxidase substrate (2,5 mg/ml in 0.1M
Citrate-phosphate buffer) and measured at 405 nm on a VersaMax microplate reader (Molecu-
lar Devices, Sunnyvale, CA, USA). Specific antibody titers against Cu2SO4-oxidized LDL
(CuOx-LDL) and malondialdehyde-modifiedLDL (MDA-LDL) were determined as described
previously [20].
Flow Cytometry
Peritoneal and splenic B lymphocyte subsets were analyzed on a BD FACS Canto II flow
cytometer (Becton,Dickinson, Franklin Lakes, NJ, USA) by using the following antibodies:
CD19-FITC, CD5-PerCPcy5.5 and CD11b-A700 (all from eBioscience,Vienna, Austria). Lym-
phocytes were gated in the forward/side scatter and B lymphocytes were classified according to
CD19 expression and further divided into CD5+ B1a lymphocytes [8], CD5-CD11b+ B1b lym-
phocytes, and CD5-CD11b- B2 lymphocytes [21]. Samples were analyzed using FlowJo soft-
ware version 7.6.5. (FlowJo, LLC, Ashland, OR, USA).
Gene expression
From blood cells Total RNA was extracted using the AurumTM Total RNA Mini Kit (BioRad,
Hercules, CA, USA) and for the snap frozen Lymph nodes and aorta’s total RNA was extracted
after crushing (under liquid nitrogen) using Trizol (Life technologies). cDNA was made from
500ng total RNA using iScript cDNA Synthesis kit (BioRad). Semi-quantitative real-time PCR
was performed using iQ SYBR Green Supermix (BioRad) and was measured with the MyIQ
system. The following primers were designed for CD19 and Rplp0 (to correct for cDNA con-
tent) were designed (S1 Table). A TaqMan assay was done using TaqMan Gene Expression
MasterMix (Thermo Fisher Scientific,Waltham, MA, USA) and was measured on a StepOne-
PlusTM Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific).APRIL and
HPRT probes were purchased from Thermo Fisher Scientific (S1 Table).
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Cytochemical and immunohistological stainings
Paraffin sections were deparaffinized and rehydrated. Aortic root lesions were visualized using
hematoxylin-eosin (H&E) stain. Plaque size and necrotic core were quantified using Adobe
photoshop CS5 software. Plaque stage was determined according to the method described by
deWaard et al. [22]. For further plaque phenotyping, aortic roots were stained for 60 minutes
with a 0.2% Picro Sirius Red solution and incubated for 2 minutes in acidifiedwater (0.01M
HCl). The sections were dehydrated, embedded in pertex (Histolab, Västra Frölunda, Sweden)
and collagen content was quantified using Adobe photoshop CS5 software. In addition, sec-
tions were incubated with antibodies detectingmacrophages (MAC-3; BD Pharmingen, San
Jose, CA, USA), smoothmuscle cells (SMCs; 1A4; Dako, Glostrup, Denmark), and IgM (poly-
clonal; Abcam, Cambridge,MA, USA) followed by a horseradish peroxidase (HRP)-conjugated
secondary antibody. DAB substrate (ImmunoLogic,Duiven, The Netherlands) was used for
detection. After counterstaining with hematoxylin sections were embedded in pertex. Finally,
the positive stained area was quantified in 4 sections per mouse using Adobe Photoshop CS5
software and calculated as a percentage from total lesion size.
Statistical analyses
Data are presented as mean±SEM,median (IQR) or n(%). Unpaired t-tests or Mann Whitney
U tests were used to assess differences between the 2 groups depending on a normal distribu-
tion. Differences in plaque stage were assessed using a Chi square test. All data were analysed
using Prism version 5.0 (GraphPad software, La Jolla, CA, USA) and SPSS version 22.0 (SPSS
Inc., Chicago, Il, USA). A p<0.05 was considered statistically significant.
Results
APRIL overexpression does not affect lesion size
ApoE-/-APRIL-Tg mice show normal growth, are viable and fertile. APRIL mRNA expression
is significantly increased in the lymph nodes, but no increase is found in the blood compart-
ment or abdominal aorta (S1 Fig). During the course of a 12-weekWTD, ApoE-/- (n = 13) and
ApoE-/-APRIL-Tg (n = 10) mice showed comparable increments in bodyweight and plasma
lipid levels (Fig 1A and 1B). Hematological blood parameters were also similar between the
two groups (Fig 1C). Assessing the aortic roots, there was no difference in total lesion area (Fig
2A) with the majority of mice in both groups showing advanced atherosclerotic lesions (82%
in stage IV or V in ApoE-/- mice and 87% in ApoE-/-APRIL-Tg, p = 0.2821) (Fig 2B).
APRIL overexpression increases plaque smooth muscle cell content
Since lesion composition is equally important as lesion size in predicting cardiovascular out-
come, we sought to investigate lesion cellular composition as well as necrotic area. In the cur-
rent study, we observedno significant differences in macrophage content, collagen deposition
or necrotic core area between the 2 groups (Fig 3A–3C). However, SMC content was signifi-
cantly increased in ApoE-/-APRIL-Tg mice (8.2%±0.9 vs 5.5%±0.5 in ApoE-/-, p = 0.0143) (Fig
3D) indicating that the lesions may more stable in APRIL-Tg mice.
APRIL overexpression increases IgM levels and peritoneal B1a cells
Consideringprevious reports demonstrating that APRIL overexpression increases IgM [16], we
assessed IgM levels in both the lesions and plasma. Lesion IgM content was almost 2-fold higher
in ApoE-/-APRIL-Tgmice compared to ApoE-/- mice (30%±5 and 18%±4, respectively; p =
0.0479) (Fig 3E). In addition, plasma IgM levels were increased 1.6 fold (ApoE-/-: 815±77 μg/ml,
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ApoE-/-APRIL-Tg: 1286±110 μg/ml, p = 0.0015) (Fig 4A). Unexpectedly, plasma IgG levels were
also augmented in the ApoE-/-APRIL-Tgmice in comparison to controls (5692±575 μg/ml and
3459±310 μg/ml, respectively; p = 0.0017) (Fig 4B), however, this did not translate to an increase
in lesion deposition (32%±15 in ApoE-/- versus 30%±13 in ApoE-/- APRIL-Tg, p = 0.753) (Fig
4C). Further specifyingplasma IgM and IgG increases we found that the IgM increase corre-
spondedwith a significant increase in anti-cuOx-LDL and anti-MDA-LDL antibodies, whereas
the increase in IgG did not (Fig 4D and 4E). Since B1a lymphocytes are potent IgM producers [8]
and B2 lymphocytes are known for their IgG production [23], we assessed the peritoneal B lym-
phocyte subsets. Flow cytometry revealed that the total percentage of B lymphocytes was compara-
ble betweenApoE-/-APRIL-Tgmice and ApoE-/- mice (36±2 versus 34±2, respectively).Moreover,
Fig 1. Bodyweight, lipid levels and blood cell counts of ApoE-/- and ApoE-/-APRIL-Tg mice. ApoE-/- (n = 13) and ApoE-/-APRIL-Tg mice
(n = 10). Every week body weight was determined (A), plasma cholesterol and triglycerides were measured before the start of diet and after 12
weeks of WTD (B). After 12 weeks of WTD the number of blood cells were measured by a cell counter (C). Data are represented as mean
±SEM. Chol (cholesterol); WBC (white blood cells); RBC (red blood cells); Htc (hematocrit).
doi:10.1371/journal.pone.0164690.g001
The B Cell Growth Factor APRIL and Atherosclerosis
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total CD19 expression in the blood, lymph nodes and aorta showed were similar; suggesting no
differences in the amount of B cells present (S2A Fig). We did find a 24% elevation in B1a
(CD19+CD5+) lymphocytes in ApoE-/-APRIL-Tgmice (53%±3) compared to the ApoE-/- (43%±2,
p = 0.01) (Fig 5A and 5B). B1b cells (CD5-CD11b+) cells were alsomoderately increased
(ApoE-/-APRIL-Tgmice 13±1% versus ApoE-/- 17±1%, p = 0.06). The atherogenic B2 lymphocyte
subset (CD5-CD11b-) however, showed a relative decrease in ApoE-/-APRIL-Tgmice (31±3%)
compared to ApoE-/- mice (44±2%, p = 0.0009). To assess whether these changes reflected absolute
differences,we used cell concentrations of peritoneal lavage fluid to calculate CD19+ cell concen-
tration, revealing that the total number of B cells in the peritoneal cavity, was in fact significantly
increased compared to ApoE-/- (p = 0.03). Moreover, the increase of B1 cells cannot be addressed
to a decrease in B2 cells (Fig 5C). As expected,we found a similar splenic B lymphocyte subset dis-
tribution in both groups, since B1 cells mainly reside in serosal cavities (such as the peritoneum)
and are only a minor population in the spleen [24] (S2B Fig).
Discussion
The present study used a novel mouse model to investigate the effect of transgenic overexpres-
sion of APRIL on an ApoE-/- background regarding 1) atherosclerotic lesion progression; 2)
IgM production; and 3) B lymphocyte phenotype.We show that in this model, IgM levels were
Fig 2. Lesion size and stage of ApoE-/- and ApoE-/-APRIL-Tg mice. After 12 weeks of WTD lesion size (A) was
quantified and lesion stage (B) was determined in the aortic roots of ApoE-/- (n = 13) and ApoE-/-APRIL-Tg mice
(n = 10). Representative photomicrographs are shown with original magnification x25. Data are represented as
mean±SEM; Scale bars represent 1mm.
doi:10.1371/journal.pone.0164690.g002
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increased 1.5 fold; potentially mediated via an increase in B1a lymphocyte numbers. This
increase did not affect lesion size or stage, but we did observe phenotypical changes of the ath-
erosclerotic lesion, with increases in smoothmuscle cell numbers accompanied by an
unchanged macrophage content.
APRIL overexpression was associated with a significant increase of total plasma IgM levels,
as well as specific IgM antibodies against OxLDL, and a concomitant increase in plaque deposi-
tion of IgM, which coincidedwith a significant increase in B1a lymphocytes. The APRIL trans-
genic mice have been described in detail previously [16]. Briefly, expression of human APRIL
under the control of the Lck distal promoter directs transgene expression to immature
Fig 3. Lesion characteristics of ApoE-/- and ApoE-/-APRIL-Tg mice. ApoE-/- (n = 13) and ApoE-/-APRIL-Tg mice (n = 10). After 12 weeks
of WTD macrophage content (A) and the percentage of collagen deposition (B) were quantified. Representative photomicrographs and
quantification of Smooth muscle cell content (C), necrosis (D), and IgM deposition (E) are shown. Original magnification x50 (C+D) and x25
(E). Data are represented as mean±SEM; *p<0.05; Scale bars represent 1mm.
doi:10.1371/journal.pone.0164690.g003
Fig 4. Immunoglobulins of ApoE-/- and ApoE-/-APRIL-Tg mice. After 12 weeks WTD both plasma IgM (A) and IgG (B) were
measured. In ApoE-/- (n = 13) and ApoE-/-APRIL-Tg mice (n = 10) IgG deposition was quantified as a % of total lesion size (C).
Specific antibodies to copper-oxidized (CuOx) or malondialdehyde (MDA)-modified LDL (quantified as relative light units (RLU))
were determined for both IgM (D) and IgG (E) before start of the WTD and at harvest (after 12 weeks WTD). F, percentage of
CD19+ cells, as well as the percentages of each subset are shown. Data are represented as mean±SEM; **p<0.01 ***p<0.001.
doi:10.1371/journal.pone.0164690.g004
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thymocytes and peripheral T lymphocytes; after which it can bind two members of the TNF
receptor family: the transmembrane activator and calciummodulator cyclophilin ligand
Fig 5. Peritoneal B cell subsets of ApoE-/- and ApoE-/-APRIL-Tg mice. Peritoneal B cell subsets were quantified by FACS analysis after 12
weeks of WTD in ApoE-/- (n = 13) and ApoE-/-APRIL-Tg mice (n = 10). The cells were gated (A) for Lymphocytes in the FSC/SSC plot and B cells
were selected on the basis of CD19 positivity. Subsets were identified as follows: CD5+CD11b+B1a cells, CD5-CD11b+ B1b cells, and
CD5-CD11b- B2 cells. The percentages (B) and concentration (C) of CD19+ cells, as well as for each B cell subset are shown. Data are
represented as mean±SEM; *p<0.05 **p<0.01 ***p<0.001.
doi:10.1371/journal.pone.0164690.g005
The B Cell Growth Factor APRIL and Atherosclerosis
PLOS ONE | DOI:10.1371/journal.pone.0164690 November 7, 2016 9 / 13
interactor (TACI) and B cell maturation antigen (BCMA), involved in B and T cell homeostasis
and activation [15]. Importantly, in line with data on experimental arthritis [25], APRIL-Tg
mice do not show the severe adverse effects associated with BAFF receptor signaling (the
other ligand for BCMA and TACI) [7,17], exhibiting significantly lower percentages of the
atherogenic B2 lymphocyte subset. However, we could not corroborate previously reported
beneficial effects of IgM on atherosclerotic lesion size and composition, including a more sta-
ble phenotype with less necrosis [7,8,11,26]. Several explanations could contribute to the
absence of such a beneficial effect in our model. In two of the previously mentioned studies,
absolute differences in plasma IgM and plaque IgM were larger compared to the present
study. Kyaw and colleagues [7] reported an 80% decrease in plasma IgM levels in BAFF-R
deficient mice, and another group showed that adoptive transfer of B1a lymphocytes in sple-
nectomizedmice led to a 68% increase in plasma IgM [26]. In our study an overall 57%
increase was found in plasma levels, however, it has also been reported that in APRIL-TG
mice, B1 cell expansion and IgM production accumulate over time [27]. This suggests that,
whereas in the previously mentioned studies levels of IgM were stable throughout the experi-
ments, in our model levels may have been lower in the earlier stages of atherogenesis, sup-
ported by the finding that indeed specific antibodies against MDA-LDL increased over the
course of the experiment.
The observed increase in total B cell numbers was not expectedwith APRIL overexpression
[25]. Interestingly, Rincón-Arévalo and colleagues [28] recently reported that dyslipidemia fol-
lowing a high fat diet is capable of increasing total B lymphocytes (while lowering B lympho-
cyte CD19 expression) and concomitantly increasing IgG1 serum levels, attributed to intra-
cellular lipid accumulation.We also found an unexpected increase in total serum IgG in
ApoE-/-APRIL-Tg mice [25]. Recently, lipid accumulation has also been described to activate
human monocytes [29], supporting detrimental effects of continuous high blood lipid levels on
the immune system.Whether theWTDmay have influenced the increased cell numbers and
IgG serum levels found in ApoE-/-APRIL-Tg mice compared to ApoE-/-, was not addressed in
this study. However, it should be noted that the increase in total IgG levels did not result in any
increase of IgG antibodies against OxLDL or increased IgG deposition in atherosclerotic
lesions. The role of IgG antibodies in atherosclerosis is still poorly understood and both protec-
tive and detrimental effects have been described [23]; therefore it remains elusive whether the
increase in IgG contributed to the lack of effect in our study.
Finally, in contrast to a previous study which reported that serum IgM-deficient LDLR-/-
mice demonstrated a significantly accelerated atherosclerosis with increased plaque SMC con-
tent [10], we found increased SMC content with higher IgM levels. Apoptosis of smooth mus-
cle cells is considered an important feature of fibrous cap thinning, which in turn is an
important marker for plaque vulnerability and destabilization [30], eventually contributing to
the risk of rupture and subsequent CV events [31]. Increasing SMCs, has been previously asso-
ciated with a more stable-appearing phenotype [32].
Overall, we find that overexpression of APRIL on an atherogenic background increases
plasma IgM levels and plaque deposition. Although we did not find an important role for
ectopic overexpression of APRIL regarding plaque size, the phenotypical remodeling of
advanced atherosclerotic lesion warrants future research to the underlyingmechanisms and its
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S1 Fig. APRIL expression. Taqman assays were performed in blood cells, . . .. Lymph nodes
and aorta’s of ApoE-/- (n = 13) and ApoE-/-APRIL-Tg mice (n = 10) after 12 weeks of WTD.
Data are represented as mean±SD. p<0.05.
(EPS)
S2 Fig. B cell numbers in different compartments.After 12 weeks of WTD, a qRT-PCR for
CD19 expression (A) was performed on total blood cells, lymph nodes, and aorta from ApoE-/-
(n = 13) and ApoE-/-APRIL-Tg mice (n = 10) (A). Splenic B cell subsets were quantified by
FACS analysis as a percentage from total CD19+ cells (B). Subsets were identified as follows:
CD5+CD11b+B1a cells, CD5-CD11b+ B1b cells, and CD5-CD11b- B2 cells. Data are repre-
sented as mean±SD (A) or mean±SEM (B).
(EPS)
S1 File. SPSS raw data. Raw data used for the article.
(SAV)
S1 Table. Primer sequences and TaqMan probes.
(PDF)
S1 Text. SupplementalMaterials andMethods.
(PDF)
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